Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications

Area of Science:

• Endocrinology and Metabolism
• Pharmacology
• Molecular Biology

Background:

• Diabetes mellitus (DM) is characterized by chronic hyperglycemia and leads to severe complications affecting multiple organs.
• Pathogenesis involves mitochondrial reactive oxygen species (ROS) and metabolic imbalance, with the Hypoxia-inducible Factor (HIF) pathway playing a key role.
• Diabetic complications include cardiomyopathy, nephropathy, retinal damage, and impaired wound healing, contributing to high mortality.

Purpose of the Study:

• To review the therapeutic effects of roxadustat, a HIF-1α activator, on various diabetic complications.
• To elucidate the mechanisms by which roxadustat influences metabolic stability and reduces oxidative stress in diabetes.
• To provide a comprehensive overview of roxadustat's potential in treating diabetes-related organ damage.

Main Methods:

• Review of current research findings on roxadustat's effects in diabetic models.
• Analysis of roxadustat's mechanism of action, including HIF-PHD inhibition and activation of downstream pathways (VEGF, GLUT1, LDHA).
• Examination of roxadustat's impact on cardiomyopathy, nephropathy, retinal damage, and wound healing in the context of diabetes.

Main Results:

• Roxadustat activates Hypoxia-inducible Factor-1α by inhibiting HIF-PHD, enhancing transcriptional activity.
• It demonstrates regulatory effects on metabolic stability in hypoxic conditions.
• Roxadustat activates key downstream signaling pathways involved in cellular metabolism and vascular function.

Conclusions:

• Roxadustat exhibits significant therapeutic potential for managing diabetic complications.
• Its mechanism involves modulating the HIF pathway to counteract hyperglycemia-induced damage.
• Further research into roxadustat is warranted for its expanded application in treating diabetic organ damage.